Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–93.

Article  CAS  PubMed  Google Scholar 

Jiating L, Buyun J, Yinchang Z. Role of metformin on osteoblast differentiation in type 2 diabetes. BioMed Research International. 2019;2019.

Bahrambeigi S, Yousefi B, Rahimi M, Shafiei-Irannejad V. Metformin; an old antidiabetic drug with new potentials in bone disorders. Biomed Pharmacother. 2019;109:1593–601.

Article  CAS  PubMed  Google Scholar 

Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Therapeutic Adv Endocrinol Metabolism. 2021;12:2042018820980225.

Article  CAS  Google Scholar 

Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care. 2020;43(2):487–93.

Article  CAS  PubMed  Google Scholar 

Patoulias D, Papadopoulos C, Kassimis G, Karagiannis A, Doumas M. Updated meta-analysis of cardiovascular outcome trials evaluating cardiovascular efficacy of glucagon-like peptide-1 receptor agonists. Am J Cardiol. 2021;159:143–6.

Article  CAS  PubMed  Google Scholar 

Merce A, Buriman DG, Lascu A, Bînă AM, Feier HB, Petrescu L et al. Metformin reverses the Effects of Angiotensin 2 in human mammary arteries by modulating the expression of nitric oxide synthases. Serbian Journal of Experimental and Clinical Research.

Giaccari A, Solini A, Frontoni S, Del Prato S. Metformin benefits: another example for alternative energy substrate mechanism? Diabetes Care. 2021;44(3):647–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng J, Xu M, Walker V, Yuan J, Korologou-Linden R, Robinson JW et al. Evaluating the efficacy and mechanism of metformin targets on reducing alzheimers disease risk in the general population: a mendelian randomization study. medRxiv. 2022.

Top WM, Kooy A, Stehouwer CD. Metformin: a narrative review of its potential benefits for cardiovascular disease, cancer and dementia. Pharmaceuticals. 2022;15(3):312.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li T, Providencia R, Jiang W, Liu M, Yu L, Gu C, et al. Association of Metformin with the Mortality and Incidence of Cardiovascular events in patients with pre-existing Cardiovascular Diseases. Drugs. 2022;82(3):311–22.

Article  CAS  PubMed  Google Scholar 

Zhang K, Yang W, Dai H, Deng Z. Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: results from meta-analysis. Diabetes Res Clin Pract. 2020;160:108001.

Article  PubMed  Google Scholar 

Selçuk AA. A guide for systematic reviews: PRISMA. Turkish Archives of Otorhinolaryngology. 2019;57(1):57.

Article  PubMed  PubMed Central  Google Scholar 

Füller D, Jaehn P, Andresen-Bundus H, Pagonas N, Holmberg C, Christ M, et al. Impact of the Educational Level on Non-Fatal Health Outcomes following myocardial infarction. Curr Probl Cardiol. 2022;47(11):101340.

Article  PubMed  Google Scholar 

Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358.

Bain S, Druyts E, Balijepalli C, Baxter CA, Currie CJ, Das R, et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: AB ayesian meta‐analysis of survival data. Diabetes Obes Metabolism. 2017;19(3):329–35.

Article  CAS  Google Scholar 

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343.

Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34 000 patients. Circulation: Heart Failure. 2013;6(3):395–402.

CAS  PubMed  Google Scholar 

Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev. 2017;40:31–44.

Article  CAS  PubMed  Google Scholar 

Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med. 2017;166(3):191–200.

Article  PubMed  PubMed Central  Google Scholar 

Gnesin F, Thuesen ACB, Kähler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2020(6).

Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metabolism. 2011;13(3):221–8.

Article  CAS  Google Scholar 

Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60(9):1620–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):1–16.

Article  Google Scholar 

Lukito AA, Pranata R, Henrina J, Lim MA, Lawrensia S, Suastika K. The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(6):2177-83.

Monami M, Candido R, Pintaudi B, Targher G, Mannucci E, Delle Monache L, et al. Effect of metformin on all-cause mortality and major adverse cardiovascular events: an updated meta-analysis of randomized controlled trials. Nutr Metabolism Cardiovasc Dis. 2021;31(3):699–704.

Article  CAS  Google Scholar 

Tan J, Wang Y, Liu S, Shi Q, Zhou X, Zhou Y, et al. Long-acting metformin vs. metformin immediate release in patients with type 2 diabetes: a systematic review. Front Pharmacol. 2021;12:669814.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blumenberg A, Benabbas R, Sinert R, Jeng A, Wiener SW. Do patients die with or from metformin-associated lactic acidosis (MALA)? Systematic review and meta-analysis of pH and lactate as predictors of mortality in MALA. J Med Toxicol. 2020;16(2):222–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu Y, Lei M, Ke G, Huang X, Peng X, Zhong L, et al. Metformin use and risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease—a systematic review and meta-analysis. Front Endocrinol. 2020;11:559446.

Article  Google Scholar 

Mannucci E, Gallo M, Giaccari A, Candido R, Pintaudi B, Targher G, et al. Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: an updated meta‐analysis of randomized controlled trials with external adjudication of events. Diabetes Obes Metabolism. 2023;25(2):444–53.

Article  CAS  Google Scholar 

Moin T. Should adults with prediabetes be prescribed metformin to prevent diabetes mellitus? Yes: high-quality evidence supports metformin use in persons at high risk. Am Family Phys. 2019;100(3):134–5.

Google Scholar 

Herman WH, Ratner RE. Metformin should be used to treat prediabetes in selected individuals. Diabetes Care. 2020;43(9):1988–90.

Article  PubMed  Google Scholar 

Wilmanns JC, Pandey R, Hon O, Chandran A, Schilling JM, Forte E, et al. Metformin intervention prevents cardiac dysfunction in a murine model of adult congenital heart disease. Mol Metabolism. 2019;20:102–14.

Article  CAS  Google Scholar 

Schernthaner G, Brand K, Bailey CJ. Metformin and the heart: update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism. 2022:155160.

Slater RE, Strom JG, Methawasin M, Liss M, Gotthardt M, Sweitzer N, et al. Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance. J Gen Physiol. 2019;151(1):42–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khan SZ, Rivero M, Nader ND, Cherr GS, Harris LM, Dryjski ML, et al. Metformin is associated with improved survival and decreased cardiac events with no impact on patency and limb salvage after revascularization for peripheral arterial disease. Ann Vasc Surg. 2019;55:63–77.

Article  PubMed  Google Scholar 

Stanley W. Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy. Eur Heart J Supplements. 2001;3(supplO):O2–O7.

Article  Google Scholar 

Kim G-W, Kim Y-H, Jeong G-W. Ischemic heart disease and heart failure: advanced magnetic resonance spectroscopy and metabolic imaging. Cardiovasc Imaging Asia. 2018;2(4):176–86.

Article  Google Scholar 

Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, et al. Mitochondrial function as a therapeutic target in heart failure. Nat Reviews Cardiol. 2017;14(4):238–50.

Article  CAS  Google Scholar 

Bertero E, Maack C. Metabolic remodelling in heart failure. Nat Reviews Cardiol. 2018;15(8):457–70.

Article  CAS  Google Scholar 

Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic effects of metformin in the failing heart. Int J Mol Sci. 2018;19(10):2869.

Article  PubMed  PubMed Central  Google Scholar 

Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data. Nutr Metabolism Cardiovasc Dis. 2017;27(8):657–69.

Article  CAS  Google Scholar 

Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes. 2012;61(4):944–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Silljé HH, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011;301(2):H459–H68.

Article  CAS  PubMed